Merck marks a return to cardiology; what's next for Esperion after heart attack prevention data

Taking stock of the drug industry, from the lab to the medicine chest

March 6, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | With a potent new medicine, Merck marks a return to cardiology The medicine, sotatercept, appeared to yield numerous benefits for patients with a rare condition called pulmonary arterial hypertension. By Matthew Herper STAT+ | By cutting insulin prices, Eli Lilly avoids paying big Medicaid rebates Eli Lilly was about to run into a Medicaid penalty for hiking the price of its insulins faster than the rate of inflation. By John Wilkerson Opinion: Congress must fix the IRA's small molecule penalty A change wrought by the Inflation Reduction Act puts the development of small molecule drugs at a disadvantage compared to biologics. By John Stanford Matthew Herper/STAT STAT+ | After its drug was shown to prevent heart attacks, what's next for Esperion? Nexletol was intended to be the big alternative to statins. New findings give it a better chance of taking off, but challenges remain. By Matthew Herper STAT+ | Foundation charges cancer patients $83,000 for unproven but promising experimental drug Unlike most people who receive medications yet to be cleared by the FDA, these patients are not getting vaccines as part of a clinical trial. By Jonathan Saltzman — Boston Globe

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser